effect of aminoguanidine on plasminogen activator inhibitor-1 and receptor of advanced glycation endproduct in the liver of streptozotocin-induced diabetic rats

Objectives: advanced glycation end products (ages) play an important role in the development and progression of diabetic complications. the receptor for age (rage) is the ligand-binding site of age that initiates and accelerates the atherosclerotic process. plasminogen activator inhibitor-1 (pai-1) is a prothrombotic factor that has been proposed as a biological marker for prognostic assessment, monitoring of microvascular and macrovascular complications in diabetes. the purpose of this study is to investigate the effects of aminoguanidine on rage and pai-1 expression levels in the liver of streptozotocin-induced diabetic rats.methods: diabetes was induced in rats by intraperitoneal injection of streptozocin (stz, 50 mg/kg). on day 3, diabetic rats were administered 50, 100, and 200 mg/kg/day of aminoguanidine. the expression of pai-1 and rage in the liver tissue was evaluated using real-time pcr.results: pai-1 and rage gene expression levels were higher in the liver of the diabetic rats compared to the control group. aminoguanidine at 50, 100, and 200 mg/kg decreased pai-1 and rage gene expression in the liver (p<0.001 at all doses). however, these genes were downregulated only at a dose of 200 mg/kg in healthy rats (p<0.0001). in addition, hepatic age protein levels were significantly decreased following treatment of the diabetic rats with aminoguanidine (p<0.001). there was also a significant correlation between age protein concentration and the expression of pai-1 and rage.conclusion: in summary, the data of the present study suggest that aminoguanidine reduced the expression of pai-1 and rage in the liver of the diabetic rats.